STAAR Surgical Company STAA
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About STAA
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
STAAR Surgical Company (NASDAQ: STAA) is a medical technology company focused on ophthalmic surgery, specializing in implantable lenses used to correct refractive vision disorders. The company operates within the global eye care and medical device industries, with its primary business centered on the development, manufacture, and commercialization of implantable Collamer® lenses (ICLs) for myopia, astigmatism, and related refractive conditions. STAAR’s core revenue driver is its EVO family of implantable lenses, which are used as an alternative to laser-based refractive procedures such as LASIK. The company primarily serves ophthalmic surgeons, refractive surgery clinics, and eye care providers across international markets.
STAAR Surgical was founded in 1982 and is headquartered in Lake Forest, California. The company evolved from a broader ophthalmic device manufacturer into a specialized refractive vision company with significant emphasis on phakic intraocular lens technology. A key differentiator is its proprietary Collamer biomaterial, designed for biocompatibility and optical performance. Over time, STAAR expanded its market presence through regulatory approvals in Europe, Asia-Pacific, and the United States, including U.S. FDA approval for the EVO Visian ICL product line. The company has established a particularly strong position in Asia, where demand for myopia correction procedures has grown substantially.
Business Operations
STAAR Surgical generates the majority of its revenue through sales of implantable lenses and related surgical products. Its principal operating business is the Implantable Collamer Lens (ICL) segment, including the EVO Visian ICL and toric lens products designed to correct nearsightedness and astigmatism. Revenue is generated through direct sales and distributor relationships with ophthalmic clinics and surgeons. The company maintains manufacturing operations for its proprietary lens technologies and relies heavily on intellectual property, specialized production processes, and regulatory certifications across multiple jurisdictions.
The company operates internationally, with meaningful commercial exposure in Asia-Pacific, Europe, the Middle East, and the Americas. STAAR has historically derived a substantial portion of revenue from China and other Asian markets due to elevated rates of myopia among younger populations. Its operations include sales infrastructure, surgeon training programs, and distributor networks. STAAR also maintains strategic relationships with ophthalmic practices and clinical institutions to support adoption of its technologies. Public filings identify subsidiaries supporting manufacturing, distribution, and regional operations, although the company primarily operates as a focused refractive surgery device enterprise rather than a diversified conglomerate.
Strategic Position & Investments
STAAR Surgical’s strategic direction has centered on expanding adoption of the EVO ICL platform globally while increasing penetration among younger patients seeking alternatives to corneal refractive surgery. Growth initiatives have included expanded surgeon education, increased manufacturing capacity, and pursuit of additional regulatory approvals in major markets. The company has also invested in clinical research intended to support broader indications and strengthen long-term physician confidence in implantable refractive lens procedures.
The company’s strategic positioning benefits from rising global myopia prevalence, particularly in Asia, and growing demand for premium vision correction technologies. STAAR has emphasized innovation in lens design, digital physician engagement, and scalable manufacturing capabilities. While the company has not been characterized by large-scale acquisition activity relative to larger medical device peers, it has continued investing in operational infrastructure and product development to support long-term international growth. Public disclosures indicate continued emphasis on proprietary biomaterials and manufacturing technologies as competitive advantages within the refractive surgery market.
Geographic Footprint
STAAR Surgical is headquartered in Lake Forest, California, and maintains a global commercial presence across more than 75 countries through direct operations and distributor partnerships. The company has particularly strong exposure to China, Japan, South Korea, and other parts of Asia-Pacific, which collectively account for a significant share of overall revenue. Additional commercial operations extend throughout Europe, the Middle East, and the Americas.
Internationally, the company’s operational influence is closely tied to ophthalmic surgery networks and refractive procedure demand. Manufacturing and supply chain activities support global distribution, while regional sales organizations and clinical support teams assist local surgeons and providers. STAAR’s geographic diversification has become increasingly important due to varying regulatory environments and differing adoption rates for implantable refractive technologies across global markets.
Leadership & Governance
STAAR Surgical is led by an executive team with backgrounds in medical technology, ophthalmology, commercialization, and global healthcare operations. The company’s governance structure includes executive leadership oversight and a board focused on regulatory compliance, product innovation, and international growth strategy. Public communications and investor materials emphasize long-term market expansion, physician engagement, operational discipline, and refractive technology leadership as central strategic priorities.
Key executives include:
- Stephen C. Farrell – President and Chief Executive Officer
- Patrick J. Williams – Chief Financial Officer
- Carsten Hein – President, Asia Pacific
- Randy Clark – Senior Vice President, Global Sales
- John A. Vukich, M.D. – Chief Medical Officer
Information above is consistent with disclosures in SEC filings, company investor materials, and major financial and healthcare industry reporting available through public sources. Where leadership roles or operational details vary across reporting periods, the most recently publicly disclosed information has been prioritized.